OPKO Health's ModeX Therapeutics Says First Participants Dosed In Phase 1 Clinical Trial Evaluating MDX2301 For Prevention Of COVID-19

OPKO Health, Inc.

OPKO Health, Inc.

OPK

0.00

ModeX Therapeutics Inc., an OPKO Health company (NASDAQ:OPK), today announced that the first participants have been dosed in a Phase 1 clinical trial evaluating MDX2301 for the prevention of COVID-19. MDX2301 is a tetravalent bispecific antibody that has the potential to neutralize all known variants of SARS-CoV-2. The study is evaluating the safety and tolerability of MDX2301 administered via different routes in healthy volunteers and in adults at high risk for severe COVID-19. By combining multiple antibody binding domains in a single molecule, MDX2301 is designed to provide high potency and greater breadth compared to conventional monoclonal antibodies.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.